Skip to main content

ORIGINAL RESEARCH article

Front. Oncol.
Sec. Gastrointestinal Cancers: Colorectal Cancer
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1534148

The optimal time interval between neoadjuvant chemoradiotherapy and surgery for patients with an unfavorable pathological response in locally advanced rectal cancer: a retrospective cohort study

Provisionally accepted
Li Tao Wang Li Tao Wang 1Jianyong Fan Jianyong Fan 1*Yaqi Guo Yaqi Guo 1*Shipeng Shang Shipeng Shang 2Han Gao Han Gao 1*Jianfei Xu Jianfei Xu 1*Peng Gao Peng Gao 1*Enrui Liu Enrui Liu 1*
  • 1 The Affiliated Hospital of Qingdao University, Qingdao, China
  • 2 Clinical Research Center, Chongqing Three Gorges Central Hospital, Chongqing, China

The final, formatted version of the article will be published soon.

    The focus of this study was to determine the optimal time interval between neoadjuvant chemoradiotherapy (nCRT) and surgery in patients with locally advanced rectal cancer (LARC) who had an unfavorable pathological response, as well as to investigate the correlation between long-term outcomes and the duration of this interval.The present study retrospectively analyzed patients with locally advanced rectal cancer who underwent nCRT followed by total mesorectal excision between (TME) January 2018 and September 2021. Patients included in this study had an unfavorable pathological response, confirmed as tumor regression grade (TRG) 2-3. X-tile analysis was subsequently conducted to determine the optimal cut-off value for the time interval between nCRT and surgery. Furthermore, Cox proportional hazards regression analyses were performed to identify independent prognostic factors, and the Kaplan-Meier method was used to estimate long-term survival.The study cohort comprised of 114 patients (51.35%) in the longer interval group (>8 weeks), while the remaining 108 patients (48.65%) belonged to the shorter interval group (≤8 weeks).Univariable and multivariate Cox proportional hazards regression analyses revealed that a longer interval time was identified as an independent risk factor for overall survival (HR: 2.14, 95% CI:1.01-4.55, P=0.048) and disease-free survival (HR: 2.03, 95% CI: 1.09-3.77, P=0.025) among these patients. Moreover, patients in the longer interval group exhibited significantly worse OS and DFS compared to those in the shorter interval group (3-year OS: 87.2% vs 68.2%, P=0.001; 3-year DFS: 80.4% vs 62.7%, P=0.003). Furthermore, similar results were observed in subgroup analyses based on different TRG scores.The surveillance and monitoring should be promptly conducted following nCRT in order to promptly identify patients with an unfavorable pathological response, who would benefit from timely radical surgery within 8 weeks.

    Keywords: Locally advanced rectal cancer, neoadjuvant chemoradiation, tumor response grading, unfavorable pathological response, Surgical interval

    Received: 25 Nov 2024; Accepted: 27 Jan 2025.

    Copyright: © 2025 Wang, Fan, Guo, Shang, Gao, Xu, Gao and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Jianyong Fan, The Affiliated Hospital of Qingdao University, Qingdao, China
    Yaqi Guo, The Affiliated Hospital of Qingdao University, Qingdao, China
    Han Gao, The Affiliated Hospital of Qingdao University, Qingdao, China
    Jianfei Xu, The Affiliated Hospital of Qingdao University, Qingdao, China
    Peng Gao, The Affiliated Hospital of Qingdao University, Qingdao, China
    Enrui Liu, The Affiliated Hospital of Qingdao University, Qingdao, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.